市場調查報告書
商品編碼
1308363
退伍軍人症桿菌檢測市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會及預測Legionella Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球 退伍軍人症桿菌檢測市場規模達到2.855億美元。展望未來,IMARC Group預計到2028年,該市場規模將達到4.556億美元,2023-2028年期間的年複合成長率(CAGR)為8%。
退伍軍人症桿菌是一種影響下呼吸道的感染,可導致重症肺炎、龐蒂亞克熱和類似流感症狀的疾病。其檢測有助於確定血液、尿液和痰中是否存在細菌或抗原。目前有多種檢測方法可用於診斷 退伍軍人症桿菌病,包括尿抗原、配對血清學、聚合酶鏈反應(PCR)、直接螢光抗體(DFA)染色和下呼吸道分泌物培養。根據檢測結果,通常對患者使用大環內酯類、喹諾酮類、四環素、強力黴素、米諾環素、三甲雙胍和其他抗生素治療。
50歲以上的成年人更容易感染 退伍軍人症桿菌。因此,全球老年人口的增加是積極影響市場的主要因素之一。此外,吸煙和患有癌症、糖尿病、腎病、人類免疫缺陷病毒(HIV)或其他慢性疾病的人數不斷增加,這些人面臨感染和住院的風險。由於 退伍軍人症桿菌的死亡率很高,因此對其有效診斷檢測和治療的需求也在增加。此外, 退伍軍人症桿菌主要存在於不同的自然和人工水生環境中,如冷卻塔、呼吸治療設備、噴泉、噴霧裝置、水療池以及酒店、家庭和工廠的供水系統。因此,許多國家的衛生機構正在製定有效的水安全計劃(WSP),以盡量減少 退伍軍人症桿菌在水中的擴散。這反過來又增加了對工作場所建築中 退伍軍人症桿菌檢測的需求,以符合相關法規。此外,近期針對社區獲得性肺炎成人患者的診斷和治療策略的臨床試驗也促進了市場的成長。
The global legionella testing market size reached US$ 285.5 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 455.6 Million by 2028, exhibiting a growth rate (CAGR) of 8% during 2023-2028.
Legionella is an infection affecting the lower respiratory tract, which can lead to severe pneumonia, Pontiac fever, and illness with flu-like symptoms. Its testing helps to identify the existence of bacteria or antigens in blood, urine, and sputum. Presently, various testing methods are available to diagnose Legionella disease, including urinary antigen, paired serology, Polymerase Chain Reaction (PCR), Direct Fluorescent Antibody (DFA) stain, and culture of lower respiratory secretions. As per the testing results, macrolides, quinolones, tetracycline, doxycycline, minocycline, trimethoprim and other antibiotic treatments are usually administered to patients.
Adults over the age of 50 years are more likely to develop Legionella. Consequently, the increasing geriatric population worldwide represents one of the major factors influencing the market positively. Moreover, the rising number of individuals who smoke and have cancer, diabetes, kidney disease, human immunodeficiency virus (HIV), or other chronic illnesses are at the risk of infection and hospitalization. Since the mortality rate of Legionella is high, there is an increase in the demand for its effective diagnostic tests and treatments. Besides this, Legionella-causing bacteria are majorly found in different natural and artificial aquatic environments, such as cooling towers, respiratory therapy equipment, fountains, misting devices, spa pools, and water systems in hotels, homes, and factories. As a result, health agencies of numerous countries are developing an effective water safety plan (WSP) to minimize the proliferation of Legionella in the water. This, in turn, is escalating the demand for Legionella testing in workplace buildings to comply with the legislation. Furthermore, recent clinical trials on diagnostic and treatment strategies for adult patients with community-acquired pneumonia are contributing to the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global legionella testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on application and end user.
Water Testing
Microbial Culture
DFA Stain
PCR
Others
IVD Testing
Blood Culture
Urine Antigen Test
DFA Stain
PCR
Others
Diagnostic Laboratories
Hospital and Clinics
Others
Europe
Italy
Germany
France
Spain
United Kingdom
Russia
Others
North America
United States
Canada
Asia Pacific
China
Japan
Australia
South Korea
Indonesia
Singapore
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Becton, Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories Inc, Eiken Chemical Co. Ltd, Quidel Corporation, Takara Bio Inc., and Thermo Fisher Scientific Inc.